Novo Nordisk

NVONYSE
$142.37
3.52.52%
At Close: -
$142.25
-0.12-0.08%
After Hours: 7:47 PM EDT
15 minutes delayed
Novo Nordisk (NVO) ForecastNewsEarningsGuidanceDividends

Analyst Ratings

Insider TradesGovernment TradesShort Interest
Consensus Rating1
Buy
Highest Price Target1
$163.00
Lowest Price Target1
$31.00
Consensus Price Target1
$72.83

want to know what
the Bulls & Bears Say?

Novo Nordisk (NYSE:NVO) 주식, 분석가 평가, 목표 가격, 예측

Novo Nordisk A/S has a consensus price target of $72.83 based on the ratings of 29 analysis. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, BMO Capital, and Cantor Fitzgerald on July 1, 2024, June 25, 2024, and June 20, 2024, respectively. With an average price target of $161 between Cantor Fitzgerald, BMO Capital, and Cantor Fitzgerald, there's an implied 13.18% upside for Novo Nordisk A/S from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Mar
4
Apr
3
Jun
1
Jul
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Cantor Fitzgerald
BMO Capital
Argus Research
Argus Research
Morgan Stanley

1calculated from analyst ratings

Analyst Ratings for Novo Nordisk

Buy NowGet Alert
07/01/2024Buy Now12.48%Cantor Fitzgerald
Louise Chen
$160 → $160ReiteratesOverweight → OverweightGet Alert
06/25/2024Buy Now14.59%BMO Capital
Evan David Seigerman
$163 → $163MaintainsOutperformGet Alert
06/20/2024Buy Now12.48%Cantor Fitzgerald
Louise Chen
$160 → $160ReiteratesOverweight → OverweightGet Alert
06/17/2024Buy Now12.48%Cantor Fitzgerald
Louise Chen
$160 → $160ReiteratesOverweight → OverweightGet Alert
06/10/2024Buy Now12.48%Argus Research
John Eade
$125 → $160MaintainsBuyGet Alert
04/18/2024Buy Now12.48%Cantor Fitzgerald
Louise Chen
 → $160ReiteratesOverweight → OverweightGet Alert
04/12/2024Buy Now14.59%BMO Capital
Evan David Seigerman
 → $163Initiates → OutperformGet Alert
04/05/2024Buy Now12.48%Cantor Fitzgerald
Louise Chen
 → $160ReiteratesOverweight → OverweightGet Alert
04/01/2024Buy Now12.48%Cantor Fitzgerald
Louise Chen
 → $160ReiteratesOverweight → OverweightGet Alert
03/20/2024Buy Now12.48%Cantor Fitzgerald
Louise Chen
 → $160ReiteratesOverweight → OverweightGet Alert
03/08/2024Buy Now12.48%Cantor Fitzgerald
Louise Chen
$140 → $160MaintainsOverweightGet Alert
02/20/2024Buy Now-1.58%Cantor Fitzgerald
Louise Chen
 → $140ReiteratesOverweight → OverweightGet Alert
02/15/2024Buy Now-1.58%Cantor Fitzgerald
Louise Chen
 → $140ReiteratesOverweight → OverweightGet Alert
02/14/2024Buy Now-1.58%Cantor Fitzgerald
Louise Chen
 → $140ReiteratesOverweight → OverweightGet Alert
02/01/2024Buy Now-12.13%Argus Research
Jasper Hellweg
$115 → $125MaintainsBuyGet Alert
02/01/2024Buy Now-1.58%Cantor Fitzgerald
Louise Chen
$120 → $140MaintainsOverweightGet Alert
01/23/2024Buy Now-15.64%Morgan Stanley
Mark Purcell
 → $120Initiates → OverweightGet Alert
12/04/2023Buy Now-19.16%TD Cowen
Michael Nedelcovych
$105 → $115MaintainsOutperformGet Alert
12/01/2023Buy Now-19.16%Argus Research
John Eade
$110 → $115MaintainsBuyGet Alert
12/01/2023Buy Now-15.64%Cantor Fitzgerald
Louise Chen
 → $120Initiates → OverweightGet Alert
10/02/2023Buy Now-22.67%Argus Research
John Eade
 → $110Initiates → BuyGet Alert
03/28/2023Buy Now-78.21%BTIG
Justin Zelin
$10 → $15.5MaintainsBuyGet Alert
12/12/2022Buy Now1.93%TD Cowen
Michael Nedelcovych
$65 → $72.5MaintainsOutperformGet Alert
06/28/2022Buy Now—UBS
Michael Leuchten
—DowngradeNeutral → SellGet Alert
06/07/2022Buy Now—JP Morgan
Richard Vosser
—UpgradeNeutral → OverweightGet Alert
05/31/2022Buy Now—Guggenheim
Seamus Fernandez
—UpgradeNeutral → BuyGet Alert
03/16/2022Buy Now—Deutsche Bank
Emmanuel Papadakis
—UpgradeHold → BuyGet Alert
01/25/2022Buy Now—Liberum
Alistair Campbell
—DowngradeHold → SellGet Alert
12/20/2021Buy Now—JP Morgan
Richard Vosser
—DowngradeOverweight → NeutralGet Alert

FAQ

Q

What is the target price for Novo Nordisk (NVO) stock?

A

The latest price target for Novo Nordisk (NYSE:NVO) was reported by Cantor Fitzgerald on July 1, 2024. The analyst firm set a price target for $160.00 expecting NVO to rise to within 12 months (a possible 12.48% upside). 21 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Novo Nordisk (NVO)?

A

The latest analyst rating for Novo Nordisk (NYSE:NVO) was provided by Cantor Fitzgerald, and Novo Nordisk reiterated their overweight rating.

Q

When was the last upgrade for Novo Nordisk (NVO)?

A

The last upgrade for Novo Nordisk A/S happened on June 7, 2022 when JP Morgan raised their price target to N/A. JP Morgan previously had a neutral for Novo Nordisk A/S.

Q

When was the last downgrade for Novo Nordisk (NVO)?

A

The last downgrade for Novo Nordisk A/S happened on June 28, 2022 when UBS changed their price target from N/A to N/A for Novo Nordisk A/S.

Q

When is the next analyst rating going to be posted or updated for Novo Nordisk (NVO)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Novo Nordisk, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Novo Nordisk was filed on July 1, 2024 so you should expect the next rating to be made available sometime around July 1, 2025.

Q

Is the Analyst Rating Novo Nordisk (NVO) correct?

A

While ratings are subjective and will change, the latest Novo Nordisk (NVO) rating was a reiterated with a price target of $160.00 to $160.00. The current price Novo Nordisk (NVO) is trading at is $142.25, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch